Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer

Wendy Demark-Wahnefried, Stephen L George, Boyd R Switzer, Denise C Snyder, John F Madden, Thomas J Polascik, Mack T Ruffin 4th, Robin T Vollmer, Wendy Demark-Wahnefried, Stephen L George, Boyd R Switzer, Denise C Snyder, John F Madden, Thomas J Polascik, Mack T Ruffin 4th, Robin T Vollmer

Abstract

Background: The time between the diagnosis of cancer and a planned definitive surgical procedure offers a strong and direct approach for assessing the impact of interventions (including lifestyle interventions) on the biology of the target tissue and the tumor. Despite the many strengths of presurgical models, there are practical issues and challenges that arise when using this approach.

Purpose/methods: We recently completed an NIH-funded phase II trial that utilized a presurgical model in testing the comparative effects of flaxseed supplementation and/or dietary fat restriction on the biology and biomarkers associated with prostatic carcinoma. Herein, we report the rationale for our original design, discuss modifications in strategy, and relay experiences in implementing this trial related to the following topics: (1) subject accrual; (2) subject retention; (3) intervention delivery; and (4) retrieval and completion rates regarding the collection of paraffin-embedded and fresh frozen prostate tissue, blood, urine, ejaculate, anthropometric measures and survey data.

Results: This trial achieved its accrual target, i.e., a racially-representative (70% white, 30% minority) sample of 161 participants, low rates of attrition (7%); and collection rates that exceeded 90% for almost all biospecimens and survey data. While the experience gained from pilot studies was invaluable in designing this trial, the complexity introduced by the collection of several biospecimens, inclusion of a team of pathologists (to provide validated readings), and shifts in practice patterns related to prostatectomy, made it necessary to revise our protocol; lessons from our experiences are offered within this article.

Conclusions: While our experience specifically relates to the implementation of a presurgical model-based trial in prostate cancer aimed at testing flaxseed-supplemented and fat-restricted diets, many of the lessons learned have broad application to trials that utilize a presurgical model or dietary modification within various cancer populations.

Figures

Figure 1
Figure 1
Study flow diagram

References

    1. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–490.
    1. Kushi LH, Byers T, Doyle C, et al. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006;56:254–81.
    1. Lippman SM, Goodman PJ, Klein EA, et al. Designing the selenium and vitamin E cancer prevention trial (SELECT) J Natl Cancer Inst. 2005;97:94–102.
    1. Lee JJ, Lieberman R, Sloan JA, et al. Design considerations for efficient prostate cancer chemoprevention trials. Urol. 2001;57(4 Suppl 1):205–12.
    1. Thompson IM, Tangen CM, Klein EA, et al. Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol. 2005;23:8161–64.
    1. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003;9:502S–10S.
    1. Kim J, Sun P, Lam YW, et al. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1697–702.
    1. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab. 1998;12:605–23.
    1. Freeman VL, Meydani M, Hur K, Flanigan RC. Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer. 2004;101:2744–54.
    1. Griffiths K, Denis L, Turkes A, Morton MS. Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab. 1998;12:625–47.
    1. Morton MS, Turkes A, Denis L, Griffiths K. Can dietary factors influence prostatic disease? BJU Int. 1999;84:549–54.
    1. Ritch CR, Wan RL, Stephens LB, et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol. 2007;177:97–101.
    1. Webb AL, McCullough ML. Dietary lignans: potential role in cancer prevention. Nutr Cancer. 2005;51:117–31.
    1. Lands WE, Libelt B, Morris A. Maintenance of lower proportions of (n − 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n − 3) fatty acids. Biochim Biophys Acta. 1992;1180:147–62.
    1. Lin X, Switzer BR, Demark-Wahnefried W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res. 2001;21(6A):3995–99.
    1. Lin X, Gingrich JR, Bao W, et al. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urol. 2002;60:919–24.
    1. Demark-Wahnefried W, Robertson CN, Walther PJ. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urol. 2004;63:900–04.
    1. Bostwick DG, Aquilina JW. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J Cell Biochem Suppl. 1996;25:156–64.
    1. Allam CK, Bostwick DG, Hayes JA. Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol. 1996;9:742–51.
    1. Wills ML, Hamper UM, Partin AW, Epstein JI. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urol. 1997;49:367–73.
    1. Demark-Wahnefried W, Price DT, Polascik TJ, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urol. 2001;58:47–52.
    1. Simon R, Freedman LS. Bayesian design and analysis of two x two factorial clinical trials. Biometr. 1997;53:456–64.
    1. Shultz TD, Howie BJ. In vitro binding of steroid hormones by natural and purified fibers. Nutr Cancer. 1986;8:141–47.
    1. Bostwick DG, Montironi R, Nogle R, et al. Current and proposed biologic markers in prostate cancer. J Cell Biochem Suppl. 1992;16H:65–67.
    1. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev. 2002;21:111–24.
    1. Bloedon LT, Szapary PO. Flaxseed and cardiovascular risk. Nutr Rev. 2004;62(1):18–27.
    1. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9:379–85.
    1. Kasim-Karakas SE, Tsodikov A, Singh U. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr. 2006;83:774–79.
    1. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostat Dis. 2005;8:304–10.
    1. Hamalainen EK, Adlercreutz H, Puska P. Decrease of serum total and free testosterone during a low-fat high-fibre diet. J Steroid Biochem. 1983;18:369–70.
    1. Machin DCM. Statistical tables for the design of clinical trials, 2nd. Oxford: Blackwell; 1996.
    1. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J Urol. 1999;162:293–306.
    1. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–17.
    1. Morton MS, Chan PS, Cheng C. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate. 1997;32:122–28.
    1. Lampe JW, Martini MC, Kurzer MS. Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. Am J Clin Nutr. 1994;60:122–28.
    1. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174:919–22.
    1. Subar AF, Thompson FE, Kipnis V, et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol. 2001;154:1089–99.
    1. Thompson FE, Subar AF, Brown CC, et al. Cognitive research enhances accuracy of food frequency questionnaire reports: results of an experimental validation study. J Am Diet Assn. 2002;102:212–25.
    1. Kohl HW, Blair SN, Paffenbarger RS., Jr A mail survey of physical activity habits as related to measured physical fitness. Am J Epidemiol. 1988;127:1228–39.
    1. Thompson LU. Experimental studies on lignans and cancer. Baillieres Clin Endocrinol Metab. 1998;12:691–705.
    1. Stasse-Wolthuis M, Hautvast JG, Hermus RJ, et al. The effect of a natural high-fiber diet on serum lipids, fecal lipids, and colonic function. Am J Clin Nutr. 1979;32:1881–88.
    1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Therapeut. 1999;21:1074–90.
    1. Rogatko A, Babb JS, Wang H. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res. 2004;10:4645–51.
    1. Tateyama H, Tada T, Hattori H, et al. Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Arch Pathol Lab Med. 1998;122:252–55.
    1. Tefilli MV, Gheiler EL, Tiguert R, et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urol. 1999;53:372–77.
    1. Rojavin MA. Recruitment index as a measure of patient recruitment activity in clinical trials. Contemp Clin Trials. 2005;26:552–56.
    1. Bolen S, Tilburt J, Baffi C, et al. Defining “success” in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach. Cancer. 2006;106:1197–204.
    1. American Cancer Society . Cancer Facts and Figures, 2007. Atlanta: ACS; 2007.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera